Mary Bui is a pharmacist who is specialized in Pharmacotherapy in New York, New York. Patients can reach her at 585 E 68th St, New York or contact her on 212-746-0713. Active license number of Mary Bui is 051920 for Pharmacotherapy in New York. Mary Bui is a licensed pharmacist who has demonstrated specialized knowledge and skill in optimizing pharmacotherapeutic care of patients, by developing, implementing, monitoring, and modifying complex treatment plans, providing advanced level education and consultation, and collaborating with other health professionals in the management of therapy.
Complete Profile:
Mary Bui speciality, credentials, practice address, contact phone number and fax are as below. Patients can call on the below given phone number for enquiries.
Name:
Mary Bui
Specialization:
Pharmacotherapy
Gender:
Female
Location:
585 E 68th St, New York, New York, 10065-4870
Phone:
212-746-0713
Professional Identification Codes:
NPI number stands for National Provider Identifier which is a unique 10-digit identification number issued to health care providers in the United States by the Centers for Medicare and Medicaid Services (CMS).
NPI details of Mary Bui are as mentioned below.
NPI Number:
1720332901
NPI Enumeration Date:
09 Nov, 2012
NPI Last Update On:
09 Nov, 2012
Medical Licenses:
Pharmacists can have one or more medical licenses for different specialities in the same state or different states. Related medical licenses for Mary Bui are as mentioned below.
Specialization
License Number
State
Status
Pharmacotherapy
051920
New York
Primary
Business Mailing Address:
Business mailing address can be used for mailing purpose only, for visiting purpose patients need to refer above mentioned address.
Address:
2450 Morgan Ave, Bronx, New York
Zip:
10469-5706
Phone Number:
--
Fax Number:
--
Patients can reach Mary Bui at 585 E 68th St, New York, New York or can call on phone at 212-746-0713.
Comments/ Reviews:
*Data of this site is collected from Medicare & Medicaid Services (CMS) and NPPES. Last updated on 11 November, 2024.